Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1

Conditions

Melanoma 3Skin Neoplasms 2Thyroid Neoplasms 1Parotid Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Basal Cell 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 4trametinib 3pembrolizumab 3Specimen Handling 3ulixertinib 2larotrectinib 2binimetinib 2Surveys and Questionnaires 2Radiosurgery 2Nivolumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Cisplatin 2Biopsy 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1naporafenib 1lenvatinib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Erlotinib Hydrochloride × Dermatologic × Clear all
NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Thomas Jefferson University

Phase 1 Completed
13 enrolled
DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡